Abstract
Hypertensive patients with the metabolic/cardiometabolic syndrome (MetS) are at especially high risk for complications of cardiovascular disease (CVD).1-3 In addition, racial differences in the presentation of MetS are well documented. For example, when compared with white patients, black patients with MetS have a higher prevalence of elevated blood pressure, type 2 diabetes mellitus, and obesity but lower levels of triglycerides and higher levels of high-density lipoprotein cholesterol.1 The primary management strategy for MetS includes lifestyle changes, optimization of blood pressure (BP) control, and reduction of other cardiovascular risk factors.1,2

This publication has 32 references indexed in Scilit: